Efficacy and Safety of QD202 in Participants With Acute Ischemic Stroke Undergoing Thrombolysis Excluding Endovascular Thrombectomy

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 120 participants.

Also called NCT07581210

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 120 participants (planned count) (from the registry)
Sponsor
Shanghai QuietD Biotechnology Co., Ltd. (from the registry)
Registry
  • NCT NCT07581210
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07581210. Randomized; triple masking; primary purpose treatment. Start 2025-10-14 (actual); primary completion 2026-08 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of QD202 in Participants With Acute Ischemic Stroke Undergoing Thrombolysis Excluding Endovascular Thrombectomy
Condition
Acute Ischemic Stroke
Intervention (Drug)
QD202
Intervention (Drug)
Placebo
Lead sponsor
Shanghai QuietD Biotechnology Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct07581210
Content hash
2ff50646c15129ecc537a8d6d545eb03cd6629efe9f74201039e34d5f057dd2c